Last €35.00 EUR
Change Today -0.16 / -0.46%
Volume 3.0K
VETO On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
As of 11:35 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

vetoquinol sa (VETO) Snapshot

Open
€35.10
Previous Close
€35.16
Day High
€35.30
Day Low
€34.80
52 Week High
02/28/14 - €40.00
52 Week Low
11/18/13 - €27.40
Market Cap
415.9M
Average Volume 10 Days
3.6K
EPS TTM
€2.03
Shares Outstanding
11.9M
EX-Date
06/2/14
P/E TM
17.3x
Dividend
€0.37
Dividend Yield
1.06%
Current Stock Chart for VETOQUINOL SA (VETO)

Related News

No related news articles were found.

vetoquinol sa (VETO) Related Businessweek News

No Related Businessweek News Found

vetoquinol sa (VETO) Details

Vétoquinol S.A., a veterinary pharmaceutical laboratory, designs, develops, and sells veterinary drugs and non-medicinal products serving both the livestock and pet markets in Europe, the Americas, and the Asia Pacific region. It offers anti-infective, pain inflammation, and cardiology/nephrology products for dogs, cats, cattle, and pigs. The company’s products include Aurizon, Clavaseptin, Flexadin, Ipakitine, Marbocyl, Propalin, Prilium, Rubénal, Tolfine/Tolfédine, and Zentonil. The company was founded in 1933 and is headquartered in Lure, France.

1,847 Employees
Last Reported Date: 04/14/14
Founded in 1933

vetoquinol sa (VETO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

vetoquinol sa (VETO) Key Developments

Vétoquinol SA Presents at Kepler Cheuvreux Autumn Conference 2014, Sep-17-2014

Vétoquinol SA Presents at Kepler Cheuvreux Autumn Conference 2014, Sep-17-2014 . Venue: Paris, France. Speakers: Regis Vimal du Monteil, Group Director of Finance and Legal.

Vétoquinol SA Announces Earnings Results for the Second Quarter and Six Months of 2014

Vétoquinol SA announced earnings results for the second quarter and six months of 2014. For the quarter, the company’s sales growth was particularly strong in the second quarter at 8.8%. For the period, the company reported sales of €149.4 million, up 2.7% from a year ago. EBIT was €15.0 million against €14.4 million a year ago. Net income, group share was €10.4 million against €9.9 million a year ago. The improvement in EBIT reflects positive developments in the product mix, tight control of expenditure and the impact of the consolidation of Bioniche as from April 15, 2014. Operating income amounted to €14.3 million including €0.7 million in non-recurring expenses related to the Bioniche acquisition. Net financial income came in at €0.5 million, impacted by higher returns on cash investments and the inclusion of interest expenses related to the Group's two most recent acquisitions.

Vétoquinol SA Reports Sales Results for the First Quarter of 2014; Reaffirms Earnings Outlook for First Quarter and Full Year of 2014

Vétoquinol SA reported sales results for the first quarter of 2014. For the quarter, sales amounted to EUR 75.4 million, stable compared to first quarter of 2013 at constant exchange rates and consolidation scope (like for like). Taking into account a negative currency impact of 3.0%, sales came to EUR 73.2 million, compared to EUR 75.5 million in first quarter of 2013. The company remain confident about the outlook for 2014 For the first quarter of 2014 operating earnings continue to strengthen the Group's fundamentals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VETO:FP €35.00 EUR -0.16

VETO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VETO.
View Industry Companies
 

Industry Analysis

VETO

Industry Average

Valuation VETO Industry Range
Price/Earnings 16.3x
Price/Sales 1.3x
Price/Book 1.6x
Price/Cash Flow 10.9x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VETOQUINOL SA, please visit www.vetoquinol.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.